Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Pathol Res Pract ; 220: 153393, 2021 Apr.
Article de Anglais | MEDLINE | ID: mdl-33740544

RÉSUMÉ

BACKGROUND: Cadherin-5 (CDH5) is aberrantly expressed in a variety of human cancers and plays an important role in angiogenesis. The present study provides further insight into the role of miR-27a-3p in the regulation of CDH5 expression in renal clear cell carcinoma (ccRCC). METHODS: Thedysregulation of CDH5 expression in ccRCC and its association with clinicopathological characteristics were analyzed using the TCGA database. A meta-analysis was performed to verify the alteration of CDH5 expression in ccRCC using the GEO database. Quantitative RT-PCR and immunohistochemical staining were applied to assess the transcriptional and protein levels of CDH5. TargetScan and Tarbase were employed to predict the miRNAs with the potential to target mRNA of CDH5. RESULTS: The mRNA level of CDH5 in ccRCCwas significantly higher than in normal tissue. CDH5 mRNA expression could therefore serve as a potential diagnostic biomarker for ccRCC (AUC = 0.844). However, the reduced CDH5 transcription levels were significantly correlated with patients in the T3-4 stage, lymph node, and distant metastasis, as well as with a worse clinical outcome. We further observed that CDH5, at the protein level, was almost absent in ccRCC samples. In addition, a few databases screen showed that mir-27a-3p is a highly conserved miRNA targeting CDH5. The expression of mir-27a-3p was significantly elevated in ccRCC tissues in contrast to normal tissues. Importantly, it was positively associated with the T3-4 stage and M stage, respectively, suggesting that the expression level of mir-27a-3p could serve as a diagnostic biomarker for ccRCC (AUC = 0.775). CONCLUSION: Our data suggest that thereduced translational level of CDH5 in ccRCC was related to the overexpression of mir-27a-3p. The higher mir-27a-3p and lower CDH5 expression significantly correlated with advanced clinical stages for ccRCC patients.


Sujet(s)
Antigènes CD/génétique , Marqueurs biologiques tumoraux/génétique , Cadhérines/génétique , Néphrocarcinome/génétique , Mouvement cellulaire , Prolifération cellulaire , Tumeurs du rein/génétique , microARN/génétique , Antigènes CD/métabolisme , Marqueurs biologiques tumoraux/métabolisme , Cadhérines/métabolisme , Néphrocarcinome/métabolisme , Néphrocarcinome/secondaire , Néphrocarcinome/thérapie , Bases de données génétiques , Survie sans rechute , Femelle , Régulation de l'expression des gènes tumoraux , Humains , Tumeurs du rein/métabolisme , Tumeurs du rein/anatomopathologie , Tumeurs du rein/thérapie , Mâle , microARN/métabolisme , Adulte d'âge moyen , Invasion tumorale , Stadification tumorale , Valeur prédictive des tests , Appréciation des risques , Facteurs de risque , Facteurs temps
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE